- Home
- BIAF vs MTVA Comparison
BIAF vs MTVA Comparison
Compare BIAF & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIAF
- MTVA
- Stock Information
- Founded
- BIAF 2014
- MTVA 2014
- Country
- BIAF United States
- MTVA United States
- Employees
- BIAF N/A
- MTVA N/A
- Industry
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- MTVA
- Sector
- BIAF Health Care
- MTVA
- Exchange
- BIAF Nasdaq
- MTVA NYSE
- Market Cap
- BIAF 12.2M
- MTVA 14.3M
- IPO Year
- BIAF 2022
- MTVA N/A
- Fundamental
- Price
- BIAF $0.29
- MTVA $0.64
- Analyst Decision
- BIAF Hold
- MTVA Strong Buy
- Analyst Count
- BIAF 1
- MTVA 2
- Target Price
- BIAF N/A
- MTVA $7.50
- AVG Volume (30 Days)
- BIAF 11.2M
- MTVA 142.2K
- Earning Date
- BIAF 08-13-2025
- MTVA 08-13-2025
- Dividend Yield
- BIAF N/A
- MTVA N/A
- EPS Growth
- BIAF N/A
- MTVA N/A
- EPS
- BIAF N/A
- MTVA N/A
- Revenue
- BIAF $8,809,228.00
- MTVA N/A
- Revenue This Year
- BIAF N/A
- MTVA N/A
- Revenue Next Year
- BIAF $20.00
- MTVA N/A
- P/E Ratio
- BIAF N/A
- MTVA N/A
- Revenue Growth
- BIAF 78.40
- MTVA N/A
- 52 Week Low
- BIAF $0.16
- MTVA $0.63
- 52 Week High
- BIAF $2.99
- MTVA $5.30
- Technical
- Relative Strength Index (RSI)
- BIAF 50.96
- MTVA N/A
- Support Level
- BIAF $0.22
- MTVA N/A
- Resistance Level
- BIAF $0.46
- MTVA N/A
- Average True Range (ATR)
- BIAF 0.04
- MTVA 0.00
- MACD
- BIAF 0.01
- MTVA 0.00
- Stochastic Oscillator
- BIAF 30.51
- MTVA 0.00
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
About MTVA METAVIA INC
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.